AbbVie Bails On Harpoon’s Multiple Myeloma Drug Amid Highly Competitive Environment

AbbVie decided not to exercise its option for Harpoon's multiple myeloma drug candidate • Source: Shutterstock

More from Immuno-oncology

More from Anticancer